CytomX Therapeutics, Inc. (CTMX)

Market Cap	155.06M
Revenue (ttm)	119.18M
Net Income (ttm)	16.53M
Shares Out	77.92M
EPS (ttm)	0.20
PE Ratio	10.00
Forward PE	53.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,644,798
Open	1.980
Previous Close	1.960
Day's Range	1.930 - 2.010
52-Week Range	1.040 - 5.850
Beta	1.03
Analysts	Buy
Price Target	6.53 (+226.5%)
Earnings Date	May 8, 2024

About CTMX

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 8, 2015
• Employees: 120
• Stock Exchange: NASDAQ
• Ticker Symbol: CTMX

Financial Performance

In 2023, CTMX's revenue was $101.21 million, an increase of 90.38% compared to the previous year's $53.16 million. Losses were -$569,000, -99.43% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for CTMX stock is "Buy." The 12-month stock price forecast is $6.53, which is an increase of 226.50% from the latest price.

Price Target

$6.53

(226.50% upside)

Analyst Consensus: Buy